Abstracts tagged "Biomarkers"

Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium
Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)
Sean Donohue ¹, Angela Midgley ¹, Jennifer Davies ¹, Rachael Wright ¹, Ian Bruce ², Michael Beresford ¹ and Christian Hedrich¹, ¹University of Liverpool, Liverpool, United Kingdom, ²The University of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis ¹, Denise Pires Marafon ², Ivan Caiello ², Manuela Pardeo ², Giulia Marucci ², Emanuela Sacco ², Giusi Prencipe ², Fabrizio De Benedetti ² and Claudia Bracaglia², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium
Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
Claas Hinze¹, Tanja Hinze ², Helmut Wittkowski ¹, Christoph Kessel ¹, Sabrina Fuehner ¹ and Dirk Foell ¹, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²Muenster, Nordrhein-Westfalen, Germany
Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
Abstract Number: 156 • 2020 Pediatric Rheumatology Symposium
Metabolic Profiling in Juvenile Dermatomyositis
Jeffrey Dvergsten¹, Olga Ilkayeva ², Lawrence Landerman ², Michael Muehlbauer ³, David Pisetsky ⁴, Ann Reed ³ and Kim Huffman ⁵, ¹Duke University Hospital, Hillsborough, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University Medical Center, Durham, ⁵Durham
Background/Purpose: Investigators have made significant progress piecing together pathogenic mechanisms of juvenile dermatomyositis (DM). However, this remains an incomplete puzzle, and optimal approaches to diagnosing,…
Abstract Number: 162 • 2020 Pediatric Rheumatology Symposium
Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)
Terry Moore¹, Austin Dalrymple ², Lance Feller ³ and Paul Tuttle ⁴, ¹ST. LouisUniv12651729, St. Louis, Missouri, ²Saint Louis University School of Medicine, Saint Louis, Missouri, ³Orlando, Florida, ⁴OSMS, Hobart, Wisconsin
Background/Purpose: JIA is a heterogeneous group of patients with varying types of biomarkers detected in a small percentage of patients. More specific biomarkers would help…
Abstract Number: 163 • 2020 Pediatric Rheumatology Symposium
Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies
Asa Laestadius¹, May Choi ¹, Marvin Fritzler ¹, Aurore Fifi-Mah ², Susanne Benseler ³ and Joao Dantas ¹, ¹University of Calgary, Calgary, Canada, ²Calgary, Canada, ³Univeristy of Calgary, Calagry, Canada
Background/Purpose: Autoantibodies to dense fine speckles 70 (DFS70) is now recognized to be more common among apparently healthy individuals compared to patients with ANA-related rheumatic…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
David Isenberg¹, Richard Furie ², Nicholas Jones ³, Pascal Guibord ⁴, Joshua Galanter ⁵, Chin Lee ³, Anna McGregor ³, Balazs Toth ³, Julie Rae ³, Olivia Hwang ³, Pedro Miranda ⁶, Viviane de Souza ⁷, Juan Jaller-Raad ⁸, Anna Maura Fernandes ⁹, Rodrigo Garcia Salinas ¹⁰, Leslie Chinn ³, Michael Townsend ¹¹, Alyssa Morimoto ³ and Katie Tuckwell ¹², ¹University College London, London, United Kingdom, ²Northwell Health, Great Neck, NY, ³Genentech, Inc., South San Francisco, California, ⁴Hoffmann-La Roche Limited, Mississauga, Canada, ⁵Genentech, Inc., SOUTH SAN FRANCISCO, ⁶Centro Estudios Reumatologicos, Santiago, Chile, ⁷Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, ⁸Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, ⁹Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, ¹⁰Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ¹¹Genentech, Inc., San Fransisco, ¹²Genentech, Inc., South San Francisco, CA
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
Abstract Number: 698 • 2019 ACR/ARP Annual Meeting
Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
Ilana Abeles¹ and Vasileios Kyttaris ², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Gene expression studies have previously demonstrated increased Type I interferon α (IFN) inducible genes in peripheral blood mononuclear cells of systemic lupus erythematosus (SLE)…
Abstract Number: 1827 • 2019 ACR/ARP Annual Meeting
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Stanley Moore ¹, Hsin-Hsuan Juo ¹, Christoffer Nielsen ², Helena Tyden ³, Anders Bengtsson ³ and Christian Lood¹, ¹University of Washington, Seattle, ²Statens Serum Institut, Copenhagen, Denmark, ³Lund University, Lund, Sweden
Background/Purpose: Neutrophil activation, including formation of neutrophil extracellular traps (NETs), is essential in host defense. However, NET formation has also been linked to inflammation and…
Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 784 • 2019 ACR/ARP Annual Meeting
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Cristina Segu-Verges¹, Mireia Coma ¹, Christoph Kessel ², Serge Smeets ³, Dirk Foell ² and Anna Aldea ⁴, ¹Anaxomics, Barcelona, Catalonia, Spain, ²University Hospital Muenster, Muenster, Germany, ³Novartis, Amsterdam, Netherlands, ⁴Novartis, Barcelona, Catalonia, Spain
Background/Purpose: Systemic JIA (sJIA) and Adult Onset Still’s Disease may represent a disease continuum1 of the same autoinflammatory disorder, Still’s Disease. Current challenges in its…
Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Julio Ramirez¹, Andrea Cuervo Aguilera ², Raquel Celis ³, Virginia Ruiz-Esquide ³, Raul Castellanos-Moreira ⁴, Jose Gomez-Puerta ⁵, Raimon Sanmarti ⁵ and Juan Cañete ⁵, ¹Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Hospital Clínic Barcelona, Spain, Barcelona, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].